In Sequence: a genomics podcast by Genuity Science
In Sequence: a genomics podcast by Genuity Science
4 episodes
6 months ago
In episode 8, we talk to Dr. Scott Friedman, internationally renowned physician and scientist, who explains why Non-alcoholic steatohepatitis or NASH is a liver disease that is becoming a growing health concern world-wide. Dr. Friedman describes the extraordinary capacity for the liver to regenerate, his ground-breaking research into the cause of inflammation and resulting scarring or fibrosis of the liver, and how Whole Genome Sequencing is being used to improve our understanding of why some people have a higher risk of developing the condition than others. Finally, he talks about how drug companies are leveraging all of this growing information in order to develop better diagnostics and new effective treatments for NASH and other forms of chronic liver disease.
All content for In Sequence: a genomics podcast by Genuity Science is the property of In Sequence: a genomics podcast by Genuity Science and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In episode 8, we talk to Dr. Scott Friedman, internationally renowned physician and scientist, who explains why Non-alcoholic steatohepatitis or NASH is a liver disease that is becoming a growing health concern world-wide. Dr. Friedman describes the extraordinary capacity for the liver to regenerate, his ground-breaking research into the cause of inflammation and resulting scarring or fibrosis of the liver, and how Whole Genome Sequencing is being used to improve our understanding of why some people have a higher risk of developing the condition than others. Finally, he talks about how drug companies are leveraging all of this growing information in order to develop better diagnostics and new effective treatments for NASH and other forms of chronic liver disease.
Ep 6: Chasing a Cure: Searching for answers to Congenital Hyperinsulinism leveraging genomics
In Sequence: a genomics podcast by Genuity Science
31 minutes 47 seconds
4 years ago
Ep 6: Chasing a Cure: Searching for answers to Congenital Hyperinsulinism leveraging genomics
In celebration of Rare Disease Day, we hear from a panel of five inspiring guests - all who share their unique perspectives about one particular rare condition called Congenital Hyperinsulinism. Join us to hear these valuable insights from Julie Raskin – Co-Founder and Executive Director, Congenital Hyperinsulinism International (CHI), New Jersey, and mom to Ben who has congenital hyperinsulinism; Sheila Bose – Vice President of the Board of Directors for CHI and parent to 3 children born with congenital hyperinsulinism; Dr Sarah Flanagan - Associate Professor in Genomic Medicine at the University of Exeter Medical School; Dr. Diva De León-Crutchlow - Chief of Endocrinology and Diabetes and Director of the Congenital Hyperinsulinism Center at Children's Hospital of Philadelphia; and Dr. Paul Thornton – Medical Director of the Endocrine and Diabetes Program at Cook Children’s Medical Center, Texas.
In Sequence: a genomics podcast by Genuity Science
In episode 8, we talk to Dr. Scott Friedman, internationally renowned physician and scientist, who explains why Non-alcoholic steatohepatitis or NASH is a liver disease that is becoming a growing health concern world-wide. Dr. Friedman describes the extraordinary capacity for the liver to regenerate, his ground-breaking research into the cause of inflammation and resulting scarring or fibrosis of the liver, and how Whole Genome Sequencing is being used to improve our understanding of why some people have a higher risk of developing the condition than others. Finally, he talks about how drug companies are leveraging all of this growing information in order to develop better diagnostics and new effective treatments for NASH and other forms of chronic liver disease.
